Tenlifast-M 500SR – Uses, MOA, Benefits, and Recommended Dosage

  • Post category:Blog
  • Post comments:0 Comments
  • Reading time:7 mins read
Tenlifast-M 500SR

Introduction:

Tenlifast-M 500SR, a flagship creation by Invision Medi Sciences, combines the efficacy of Teneligliptin Hydrobromide Hydrate (20 mg) and Extended-Release Metformin Hydrochloride (500 mg). This guide explores the uses, benefits, recommended dosage, and the dynamic synergy of Tenlifast-M 500SR, facilitating comprehensive diabetes care.

Teneligliptin and Extended-Release Metformin: A Unified Approach to Glycemic Control:

Tenlifast-M 500SR features Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Extended-Release Metformin, an established antidiabetic agent. Together, they offer a comprehensive solution for managing diabetes by addressing both insulin resistance and glucose production.

Indications for Tenlifast-M 500SR:

  1. Type 2 Diabetes: Tenlifast-M 500SR is indicated for the management of type 2 diabetes, promoting optimal glycemic control.
  2. Dual Action: Teneligliptin and Extended-Release Metformin work synergistically to regulate blood glucose levels.

Benefits of Tenlifast-M 500SR:

  1. Glucose Regulation: Teneligliptin enhances insulin secretion, while Extended-Release Metformin reduces hepatic glucose production, ensuring balanced glycemic control.
  2. Convenient Dosage: The extended-release formulation provides sustained release, allowing for once-daily dosing and improved patient adherence.

Recommended Dosage:

Healthcare providers determine the appropriate dosage based on individual health needs. Consistent adherence to the prescribed dosage is crucial for effective diabetes management.

Potential Side Effects:

While generally well-tolerated, some individuals may experience mild side effects:

  • Gastrointestinal Distress: Occasional gastrointestinal discomfort may occur.
  • Hypoglycemia: Monitoring blood glucose levels is crucial to prevent hypoglycemia.

Essential Information:

  1. Regular Monitoring: Regular blood glucose monitoring and follow-up consultations with healthcare providers are recommended.
  2. Patient Education: Patients are educated on recognizing and managing hypoglycemic symptoms for proactive care.

Conclusion:

Tenlifast-M 500SR, enriched with Teneligliptin and Extended-Release Metformin, exemplifies Invision Medi Sciences’ commitment to advancing diabetes care. Its dual-action approach addresses key aspects of diabetes pathophysiology for optimal glycemic control.

Related Combinations:

  1. Tenlifast-M 1000 SR: Comprehensive glycemic control with Teneligliptin and Extended-Release Metformin.
  2. Tenlifast-20: Redefining precision in glycemic control with the efficacy of Teneligliptin 20 mg tablets.

Discover the synergy of our diabetes care offerings at Invision Medi Sciences.

Tenlifast-M 500SR: Redefining diabetes care with the unified power of Teneligliptin and Extended-Release Metformin.

FAQs


How does Tenlifast-M 500SR work in managing diabetes?

Tenlifast-M 500SR combines Teneligliptin’s insulin-enhancing action with Extended-Release Metformin’s glucose-reducing effect for comprehensive diabetes management.

Is Tenlifast-M 500SR suitable for all stages of type 2 diabetes?

Tenlifast-M 500SR is indicated for the management of type 2 diabetes. Individual assessments by healthcare providers determine suitability for various stages.

Can Tenlifast-M 500SR cause hypoglycemia?

Hypoglycemia may occur, and monitoring blood glucose levels is crucial. Patient education on recognizing and managing hypoglycemic symptoms is emphasized.

What is the advantage of the extended-release formulation in Tenlifast-M 500SR?

The extended-release formulation allows for once-daily dosing, providing sustained release for improved patient adherence and convenience.

Are dietary modifications necessary while using Tenlifast-M 500SR?

While specific dietary modifications may not be required, maintaining a balanced diet is essential for overall diabetes management.

Leave a Reply


The reCAPTCHA verification period has expired. Please reload the page.